Curi Bio Launches Nautilus™ and Stingray™ Platforms for Advancing Translational Research

Portfolio company Curi Bio, innovating human stem cell-based platforms for drug discovery, announced the commercial launch of its Nautilus™ and Stingray™ platforms for advancing preclinical drug discovery. As an integrated part of Curi Bio’s growing ecosystem of preclinical human modeling platforms, these innovative technologies promise to transform the way researchers can assess physiologically relevant data such as safety and efficacy earlier in the drug discovery process saving time and money